Pierre-Guillaume Poureau
23 works · 824 citations · h-index 8
Top works
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
- 613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
- O-9 Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
- 614P Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
- Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
- Three cases of immune cholangitis related to anti–programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer
- Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
- Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
- Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
- Dose to cardiac substructures and cardiovascular events in esophageal cancer patients treated with definitive radiotherapy
- Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular CarcinomasFondamentaux de l’immunologie des Cancers Digestifs (Gastriques et Hépatocellulaires)
- Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.
- 1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort
- Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial.
- Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
- MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer
- Tolerance and Efficacy of Regorafenib according to UGT Pharmacogenetical Status in the Treatment of Metastatic Refractory Colorectal Cancer
- Surveillance tomodensitométrique des personnels de l’arsenal de Brest exposés à l’amiante : suivi d’une cohorte à 5ans
- Métastase intra thyroïdienne d’un adénocarcinome de la jonction oeso-gastrique chez un homme de 76 ans